Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R ... - APA OTS (Pressemitteilung)

Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R ... APA OTS (Pressemitteilung), Austria Maidenhead, England (ots/PRNewswire) - - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained ... - PR Newswire (press release)

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained ... PR Newswire (press release), NY REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). ...

Treating psoriatic arthritis: One-year data positive for sustained ... - Modern Medicine

Modern Medicine

Treating psoriatic arthritis: One-year data positive for sustained ... Modern Medicine, NJ Simponi was approved for marketing in the United States for moderate-to-severe rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis at the end of April. The phase 3 trial, known as GO-REVEAL (Golimumab – A Randomized Evaluation of ...

Five-Year Data Demonstrate Initial Use of Abbott's HUMIRA ... - Insciences Organisation

Five-Year Data Demonstrate Initial Use of Abbott's HUMIRA ... Insciences Organisation, Switzerland HUMIRA is a fully human monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), moderate to severe chronic plaque psoriasis, active ankylosing spondylitis (AS), moderate to severe ...